mRNA versus protein

About the image: Neuro2A cells transfected with a control siRNA (A) or a siRNA against the protein AP-3Δ (B), and stained 48 hours later with an AP-3Δ antibody (green). The transfection leads to a marked decrease in AP-3Δ levels. Credit: Courtesy of Raphael Rozenfeld" />About the image: Neuro2A cells transfected with a control siRNA (A) or a siRNA against the protein AP-3Δ (B), and stained 48 hours later with an AP-3Δ antibody (green). The transfection leads to

Written byMelissa Lee Phillips
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

User:
Raphael Rozenfeld, Mount Sinai School of Medicine, New York

Project:
Using siRNA knockdown to identify proteins involved in opioid and cannabinoid receptor signaling

Problem:
siRNA might depress mRNA levels but not induce the expected phenotype.

Controls:
Looking for a decrease in levels of your targeted mRNA isn't enough, Rozenfeld says; you should also look for reduced levels of that mRNA's protein. "Make sure that your siRNA leads to a specific decrease in the targeted protein," he says - otherwise, you won't see a phenotype. You'll need to know your protein's half-life to estimate the timeframe in which mRNA knockdown should affect your protein levels.

"Although it is often recommended testing whether the siRNA worked 48 to 72 hours after the knockdown, it is also best to check it after 24 and 96 hours," suggests Pekovic, to ensure that you don't miss the effects of particularly short- or long-lived proteins.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies